Figure 7.

Mixtures of HALA antibodies with enhanced FcγRIIa activity and blocking antibodies maximize activity and selectivity while minimizing tradeoffs. (a-b) The fold activation of FcγRIIa (ADCP reporter cells) for mixtures of wild-type trastuzumab with enhanced Fc2 (wt-eFc2) and different ratios of a blocking antibody corresponding to (a) HER2+++ and (b) HER2+ cells, as well as (c) the ratio of HER2+++/HER2+ activities. (d-e) The fold activation for mixtures of S12-eFc2 with different ratios of the blocking antibody corresponding to (d) HER2+++ and (e) HER2+ cells, as well as (f) the ratio of activities. (g-h) The fold activation for mixtures of S4-eFc2 with different ratios of the blocking antibody corresponding to (g) HER2+++ and (h) HER2+ cells, as well as (i) the ratio of activities. (j-l) Comparison of the maximum activities relative to the maximum selectivities for (j) wt-eFc2:blocker mixtures, (k) S12-eFc2:blocker mixtures and (l) S4-eFc2:blocker mixtures. In (a-l), the data are averages of three independent experiments, and the error bars are standard errors. In (k-l), the gray data and line correspond to the wt-eFc2:blocker data shown in (j).